SuperworthMaxcyte MXCT
- Market cap
- $144.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $31.1M
- −13% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −16.4%
Maxcyte trades at 4.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $31.1M over the last twelve months, down 13% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8M−25% | $15.7M+26% | $11.3M+32% | $10.4M+15% | $8.2M+2% | $8.7M−45% | $10.4M−8% | $8.5M−18% | $6.8M−16% | $7.3M−16% | $9.7M−7% | $7.3M−15% | |
| Cost of revenue | $793.4K−42% | $1.6M+2% | $1.4M+40% | $1.5M+8% | $1.9M+143% | $2.3M+45% | $1.5M+7% | $1.5M+2% | $1.6M−17% | $1.6M−29% | $1.6M+5% | $1.7M+10% |
| Gross profit | $7.2M−22% | $14.1M+30% | $9.9M+31% | $8.9M+17% | $6.2M−14% | $6.4M−55% | $8.9M−11% | $7M−22% | $5.2M−16% | $5.7M−11% | $8.1M−9% | $5.6M−20% |
| R&D | $6.3M+18% | $5.8M+2% | $6.7M+10% | $5.6M−1% | $5.3M−15% | $4.6M−21% | $5.9M−12% | $6.3M+12% | $5.3M+0% | $3.3M−28% | $3.9M−35% | $4.3M−32% |
| SG&A | $13.9M+27% | $15.3M+39% | $14.5M+5% | $14.3M+1% | $14M+1% | $13.7M−11% | $14.2M−2% | $13.9M−3% | $10M−29% | $9M−34% | $9.4M−34% | $10.6M−23% |
| −$14M+81% | −$8.1M+20% | −$12.3M−7% | −$12M−9% | −$14.1M+1% | −$12.9M+59% | −$12.3M+0% | −$14.2M+19% | −$14.1M+1% | −$11.2M−13% | −$6.2M−50% | −$10.2M−28% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$11.3M | −$5.3M | −$9.5M−13% | −$9.4M−11% | −$11.6M+3% | −$10.6M+101% | −$10.3M+8% | −$12.4M+32% | −$12.4M+7% | −$9.6M−9% | −$4.8M−54% | −$8.9M−28% |
| Net income | −$11.3M+75% | −$5.3M+10% | −$9.5M−13% | −$9.4M−11% | −$11.6M+3% | −$10.6M+101% | −$10.3M+8% | −$12.4M+32% | −$12.4M+7% | −$9.6M−9% | −$4.8M−54% | −$8.9M−28% |
| −$0.11+83% | −$0.05+0% | −$0.09−18% | −$0.09−10% | −$0.11+0% | −$0.10+100% | −$0.10+11% | −$0.12+33% | −$0.12+9% | −$0.09−10% | −$0.04−60% | −$0.08−33% | |
| 103.4M+2% | 103.7M+2% | 104.1M+1% | 104.6M+2% | 105.1M+2% | 105.5M+2% | 106M+2% | 106.4M+2% | 106.6M+1% | 106.7M+1% | 106.9M+1% | 106.8M+0% |
Revenue: Q1 FY20: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20: 6 months less the 3 months printed beside them.
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Maxcyte's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MXCTMaxcyte | $144.5M | n/m | n/a | 4.7× | −13% | n/m | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $202.4M | 14.9× | 20.7× | 2.2× | +6% | 10.6% |
More on Maxcyte
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .